Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

Ib Clinical Trial of ANA598. Anadys has completed preparations required to initiate a Phase Ib clinical trial of ANA598, an investigational oral non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV) infection, and expects to initiate patient dosing shortly. ANA598 will be administered to naive genotype 1a and 1b patients at 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid over a period of three days. Anadys expects to have viral load data from this study in the first quarter of 2009. Based on the data from the first three cohorts, Anadys may elect to explore once daily dosing and/or other dose levels of ANA598.

-- Conclusion of Healthy Volunteer Study in Phase I Clinical Trial of ANA598. In September, Anadys announced preliminary results of the Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in HCV infected patients. ANA598 was well tolerated at all doses tested, and all doses achieved plasma drug concentrations predicted to display substantial antiviral activity based on preclinical data. Safety and PK data from all dose levels in the Phase I clinical trial of ANA598 will be presented in a late-breaker poster session on November 3 at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held in San Francisco, California. Further preclinical data on ANA598 will be presented at AASLD in two additional poster presentations on November 4.

-- Initiation of Long-Term Chronic Toxicology Studies of ANA598. In September, Anadys initiated long-term chronic toxicology studies of ANA598. If ANA598 is successful in early stage clinical trials, it is anticipated that the acceleration of these and other non-clinical activities into 2008 will enable a more rapid and continuous development path into Phase II studies during 2009.

-- Phase I Clinical Trial of ANA773 in HCV. In July, Anadys announced that it was resuming
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... CA (PRWEB) February 26, 2015 The ... online demonstration to support life extension technologies and awareness. ... UTC, Universal Coordinated Time, on March 21st 2015, in ... world. , Eric Schulke, Founder of MILE, says, ... act with urgency. The Movement for Indefinite Life Extension ...
(Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... March 9 -12, at the Ernest N. Morial ... 919 exhibitors (count as of February 19, 2015) ... community in industrial, academic, and government labs. The ... such as, but not limited to, analytical chemistry; ...
(Date:2/26/2015)... JUPITER, Fla. , Feb. 26, 2015 /PRNewswire/ ... biotechnology company whose patented and proprietary technologies are ... other proteins for the bioenergy, bio-based chemical, biopharmaceutical ... will report its financial results for year ending ... March 11, 2015 and will host a conference ...
(Date:2/26/2015)... 26, 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... at the Cowen 35 th Annual Health Care Conference ... Boston .  Lexicon management will provide an ... A webcast of the presentation will be available through Lexicon,s ... presentation will be available at www.lexpharma.com until April ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3Pittcon 2015 Announces Exposition Highlights 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... Boston Scientific Corporation (NYSE: BSX ) ... and news announcements at the 30th Annual Scientific Sessions ... 13 to 16 in Boston. Highlights of the ... II clinical trial and the ALTITUDE Clinical Science Program. ...
... packaging equipment manufacturer, Sepha Ltd, enters strategic European alliances and gears ... Achema 2009 , ... Belfast (Vocus) May 11, 2009 ... and de-blistering equipment, Sepha Ltd is boosting its ...
... Pa., May 8 BioTrends Research Group released highlights from ... a four wave syndicated research study that will track uptake ... launch. The research is based on results of a ... May 7th. 95% of the Rheumatologists surveyed were aware ...
Cached Biology Technology:Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions 2Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions 3Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions 4Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions 5Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 2Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 3Baseline Research Indicates High Interest in Centocor-Ortho Biotech's SIMPONI(R) 2
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... for cancer therapy has been identified by Monash University ... a gene involved in cancer development. , A team ... of Immunology, has identified two proteins that are involved ... telomerase that is essential if cancer cells are to ...
... accumulation of genetic damage in our cells is a major ... published today in the journal Nature by an international group ... critical gene for repairing damaged DNA grow old rapidly and ... that grow old naturally. Furthermore, the premature aging symptoms of ...
... (NRL) and Purdue University have shed light on one ... magnetic. Their description of how being magnetic "helps" ... of the Biophysical Journal. , Magnetic bacteria are found ... and lakes. The strain of bacterium the research ...
Cached Biology News:New target for cancer therapy identified 2Buildup of damaged DNA in cells drives aging 2Buildup of damaged DNA in cells drives aging 3Buildup of damaged DNA in cells drives aging 4Researchers reveal mystery of bacterial magnetism 2
... and efficient method for purification of DNA fragments ... fragments selectively absorbed in the spin column after ... room temperature for PCR product with equal volume ... DNA can be purified with a single prep ...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
Request Info...
Biology Products: